| Biomarker ID | 1620 |
| PMID | 31035590 |
| Year | 2019 |
| Biomarker | MMP9 [SNP: rs3918262; A Vs G] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 4.31 (95% CI: 1.81–10.26) |
| Effect on Pathways | Pathways include: Syndecan 1 pathway, Gastrin pathway, Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling, TWEAK signaling pathway, Endochondral ossification |
| Experiment | Overall Survival Vs No Overall Survival |
| Type of Biomarker | Prognostic |
| Cohort | 418 patients in the training cohort (76 died) and 131 patients in the validation cohort (25 died) were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.001 |
| Method Used | Allele specific PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |